The company said visibility of revenue for the next six to 24 months continues to increase, which includes visibility of around 86% of the forecast revenue for 2018/19.
In its results statement for the six months to the end of October, the company noted it had won several new contracts and repeat orders during the reporting period, while in the final two months of the year it moved further into the bio-threat detection market through another contract with the US Department of Defense.
Half-year revenue dipped to £3.69mln from £4.80mln the year before, due to the temporary downtime in manufacturing in the US as a result of the relocation of the company’s US facility, which is now fully operational and delivering orders.
The relocation means that the full-year performance will be weighted more to the second half than usual.
The reduction in revenue led a widening of the loss before tax, to £2.13mln from £1.85mln the previous year, although a reduction in operational cuts meant the losses were not as severe as they might have been.
Cash and cash equivalents at the end of October stood at £6.3mln, down from £15mln a year earlier.
The company said it continues to benefit from its customers commercially launching next-generation products that use cadmium zinc telluride (CZT) and from the increasing adoption of CZT-based technology across its target markets.
Radiation is not just fascinating to physicists. Read about the man who hunts 'hidden' radioactive objects. If he wanted to identify the isotopes he could use a Kromek D3S or GR1 or Raymon10 https://t.co/Xt2mOz7VdR via @BBC_Future— Kromek Group PLC (@kromekgroup) January 8, 2019
“Over the last three fiscal years, we have won US$80mln of contracts, across all of our core sectors, demonstrating the successful conversion of our growing order pipeline. They also demonstrate the strong and long-lasting partnerships that we are continuing to build with our commercial and large government customers across the globe,” said Dr Arnab Basu, the chief executive officer of Kromek.
“The board is confident of delivering full-year revenue growth and positive EBITDA, in line with market expectations," he added.